• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
WAT
Click for more information
0.00% $5.32

WATERCO LIMITED - Corporate Spotlight

Market Cap $187.0M  ! watchlist Created with Sketch. Add to my watchlist
Consumer Cyclical Leisure

Waterco Limited is an Australia-based company. The Company is engaged in designing and... Waterco Limited is an Australia-based company. The Company is engaged in designing and manufacturing, filtration and sanitization for the swimming pool, spa, aquaculture, and water purification sectors. The Company's geographical segments include Australia and New Zealand, Asia, and North America and Europe. The Company offers wholesale, export and manufacture of equipment and accessories in the swimming pool, spa pool, spa bath, rural pump, and water treatment industries. It is also focused on manufacturing and selling solar heating systems for swimming pools and pre-heated industrial solar systems. It also operates as a franchisor of swimming pool outlets retailing swimming pool accessories and equipment. The Company is also focused on formulating, packing, and distributing swimming pool chemicals to independent pool stores and stores in its Swimart franchise network.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

No Corporate Spotlight currently available.

(20min delay)
Last
$5.32 		Change
0.000(0.00%) 		Mkt cap ! $187.0M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
1 924 $5.40
 

Sellers (Offers)

Price($) Vol. No.
$7.53 566 1
View Market Depth
Last trade - 16.12pm 07/10/2024 (20 minute delay) ?
WAT (ASX) Chart

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome Neuren has confirmed it's received "positive" FDA responses for its Phase III trial to treat children with Phelan-McDermid syndrome.
Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program Arika Resources Ltd has received commitments from investors in support of a Placement worth $3.2 million to support gold exploration in WA
Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial Chimeric Therapeutics (ASX:CHM) has reported one leukaemia patient has shown a complete response in its latest drug trial.
Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03 Nyrada Inc has completed an in-vivo micronucleus on the effects of its NYR-BI03 drug on rats, suggesting it causes no genetic damage
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.